Isodiol International Inc. Announces The Launch of It is Pawceuticals Brand

[ad_1]

Oct three, 2019 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”), announces that Pawceuticals, the CBD-primarily based
solution line that naturally assists to restore a pet’s wellness and all round wellness, is now obtainable to acquire across the United States.

The Pawceuticals functional CBD pet items are created for dogs and cats and are scientifically formulated with a proprietary blend of adaptogens that may perhaps help in comfort, calming, wholesome gums assistance, immune assistance, itch assistance, joint assistance, kennel cough assistance, kidney assistance, liver assistance, urinary assistance and anti-aging. The Company’s items are now obtainable on the internet and is also in the course of action of developing their retail channels as effectively.

“We are excited to launch Pawceuticals, specifically with the overwhelming enthusiasm we have noticed from pet owning consumers,” mentioned President of Isodiol, Andrew Alvis. “We anticipate to continue opening up platforms globally, creating it far more quickly accessible for pet owners to get items which advantage their pets.”

Comply with Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol.

About Isodiol International Inc.

Isodiol International Inc. is focused on the nutritional wellness advantages that are derived from hemp and is a solution improvement, sales, marketing and advertising and distribution firm of hemp-primarily based Customer Packaged Goods (CPG) and options. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, like micro-encapsulations, and nano-technologies for top quality consumable and topical skin care items. Isodiol’s development technique contains the improvement of more than-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

ON BEHALF OF THE BOARD
Marcos Agramont, CEO &amp Director

INVESTOR RELATIONS:
[email protected]
604-409-4409

MEDIA Make contact with:
Christopher Hussey
[email protected]

The CSE has not reviewed, authorized or disapproved the content material of this press release.

Forward-Searching Information and facts: This news release includes “forward-searching information” inside the which means of applicable securities laws relating to statements relating to the Company’s company, proposed arrangement with creditors, items and future the Company’s company, its solution offerings and plans for sales and marketing and advertising. Though the Business believes that the expectations reflected in the forward-searching information and facts are affordable, there can be no assurance that such expectations will prove to be appropriate. Readers are cautioned not to location undue reliance on forward-searching information and facts. Such forward-searching statements are topic to dangers and uncertainties that may perhaps lead to actual benefits, efficiency and developments to differ materially from these contemplated by these statements based on, amongst other items, the dangers that the Company’s items and strategy will differ from these stated in this news release and the Business may perhaps not be in a position to carry out its company plans as anticipated. Except as necessary by law, the Business expressly disclaims any obligation and does not intend, to update any forward-searching statements or forward-searching information and facts in this news release. Though the Business believes that the expectations reflected in the forward-searching information and facts are affordable, there can be no assurance that such expectations will prove to be appropriate and tends to make no reference to profitability primarily based on sales reported. The statements in this news release are created as of the date of this release.

The CSE has not reviewed, authorized or disapproved the content material of this press release.

[ad_2]

Latest posts